AbbVie Urges ITC To Block Humira Rival Over Trade Secrets

By Dani Kass (December 20, 2021, 6:34 PM EST) -- AbbVie Inc. has asked the U.S. International Trade Commission to block imports of Alvotech's biosimilar version of the best-selling biologic Humira, claiming the Icelandic company has been poaching its employees and benefiting from its trade secrets.

In a Friday complaint, AbbVie asked the agency to investigate whether Alvotech, Teva and Ivers-Lee AG are violating Section 337 of the Tariff Act by importing an adalimumab biosimilar — called AVT02 — that relied on the misappropriation of trade secrets. Humira, used for rheumatoid arthritis and a variety of other conditions, is the best selling drug in the world, with 2020 sales surpassing $20...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!